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Myotonic dystrophy (DM1) is a dominant autosomal multisystemic disorder caused by the expansion of an unstable CTG trinucleotide repeat in the
3′ untranslated region of the DMPK gene. Nuclear accumulation of the enlarged CUG-containing DMPK transcripts has a deleterious effect on the
regulation of alternative splicing of some RNAs and has a central role in causing the symptoms of DM1. In particular, Insulin Receptor (IR) mRNA
splicing defects have been observed in the muscle of DM1 patients. In this study, we have investigated IR splicing in insulin-responsive tissues (i.e.
skeletal muscles, adipose tissue, liver) and pancreas and we have studied glucose metabolism in mice carrying the human genomic DM1 region with
expanded (N350 CTG) or normal (20 CTG) repeats and in wild-type mice. Mice carrying DM1 expansions displayed a tissue- and age-dependent
abnormal regulation of IRmRNA splicing in all the tissues that we investigated. Furthermore, these mice showed a basal hyperglycemia and glucose
intolerance which disappeared with age. Our findings show that deregulation of IR splicing due to the DM1 mutation can occur in different mouse
tissues, suggesting that CTG repeat expansions might also result in IR misplicing not only in muscles but also in other tissues in DM1 patients.
© 2007 Elsevier B.V. All rights reserved.Keywords: Myotonic dystrophy; Trinucleotide repeat; Insulin receptor; Splicing; Transgenic mice1. Introduction
Myotonic dystrophy type I (DM1) was initially described on
the basis of skeletal muscle abnormalities, such as myotonia,
weakness and atrophy [1]. It is a complex disorder, involving
various systems, and including extramuscular symptoms.
Patients often present cardiac conduction defects, cataracts,
changes in smooth muscle function, neuropsychiatric distur-
bances and endocrine abnormalities, such as testicular failure or
premature frontal pattern balding in males [1]. Previous studies
also demonstrated features of metabolic syndrome, consistent
with the four times higher risk of developing type II diabetes of
DM1 patients [2]. Clinical investigations have provided evidence
of glucose intolerance and hyperinsulinism, resulting from
whole-body insulin resistance [3], an increase in fat mass [4]
and dyslipidemia [5,6]. DM1 belongs to the family of diseases
caused by unstable repeat expansions. In DM1, these expansions⁎ Corresponding author. Tel.: +33 1 44 49 45 23; fax: +33 1 47 83 32 06.
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doi:10.1016/j.bbadis.2007.08.004correspond to CTG repeats in the 3′ untranslated region of a
serine-threonine kinase (DM protein kinase, DMPK) gene on
chromosome 19 [7–10]. In place of the five through 37 CTG
repeats observed in normal individuals [8–11], CTG arrays are
expanded from 50 up to 4000 CTG in DM1 patients. Expansions
increase over successive generations, and their size is positively
correlated with clinical severity and negatively correlated with
age at onset [1]. Furthermore, CTG repeat length increases with
age in several tissues, possibly reflecting disease progression.
This mutation has various molecular consequences that may
account for the complex and progressive multisystemic pheno-
type described in DM1 [12]. The CTG expansions lead to the
retention of mutant DMPK RNA in the nucleus, resulting in
DMPK haploinsufficiency [13,14], and alter local chromatin
structure, thereby affecting the expression of neighboring genes
[15,16]. In addition, the accumulation of large CUG-containing
transcripts has a deleterious effect on the regulation of alternative
splicing for some RNAs [17] and may titrate transcriptional
factors, leading to potential gene expression defects [18].
However, there is growing evidence to suggest that the dominant
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the multisystemic features of DM1 [17]. Direct support for this
hypothesis is provided by transgenic mouse models, in which the
expression of large CUG repeat expansions accumulating as
intranuclear foci leads to the development of certain symptoms
characteristic of DM1 [19,20]. The description of a similar
molecular mechanism due to CCTG expansions in another gene
(the zinc finger protein 9 gene, ZNF9) in myotonic dystrophy
type 2 (DM2), which has a number of important clinical features
in common with DM1, also strongly supports the hypothesis of
RNA-mediated pathogenesis [17]. Nevertheless, despite descrip-
tions of changes in the splicing and function of several genes, not
all the clinical manifestations have yet been elucidated.
Previous studies suggested that insulin response defects might
play a key role in the metabolic manifestations of DM1, poten-
tially leading to type II diabetes and abnormal muscle protein
metabolism [3,21]. More recent data have suggested that early
changes in insulin secretion may be the primary defect, occurring
before insulin resistance and glucose intolerance [22,23]. How-
ever, although the sequence of events leading to these metabolic
disturbances remains unclear, a possible molecular mechanism
for insulin resistance has been proposed.Molecular analyses have
shown that the muscles of DM1 patients contain lower than
normal levels of insulin receptor (IR) RNA and protein [24] and
display abnormal regulation of insulin receptor mRNA splicing,
associated with a weaker metabolic response in cultured skeletal
muscle cells from DM1 patients [25]. By extending these molec-
ular analyses to other insulin-responsive tissues and to pancreas,
it may be possible to define more precisely the importance of
insulin resistance in the pathogenesis of metabolic syndrome.
We studied IR splicing events and glucose metabolism in
transgenic mice carrying the human genomic DM1 region with
expanded repeats (N350 CTG, DM300-328) or a normal number
of CTG repeats (20 CTG, DM20-954) and in wild-type mice
(wt). We have previously shown that the phenotype observed in
our models depends on the level of expandedDMPKRNA. Both
homozygous and heterozygous transgenic mice with expansions
show nuclear mutant DMPK RNA retention in myoblasts [20].
However, only homozygous mice (from two independent lines)
display muscle and brain abnormalities consistent with a
dominant toxic effect of CUG repeat-containing transcripts. In
this study, we observed that homozygous transgenic mice
carrying N350 CTG displayed an age-dependent abnormal
distribution of IRmRNA isoforms in various insulin-responsive
tissues and in pancreas. Age-dependent abnormal glucose
metabolism was also observed in the mice carrying the long
repeat. Our results demonstrate that the trans effect of expanded
DMPK affects IR expression not only in muscle, but also in other
tissues involved in glucose homeostasis.
2. Materials and methods
2.1. Transgenic mice
Transgenic mice were produced and genotyped as previously described [20].
For all investigations, we compared mice carrying N350 CTG repeats (DM300-
328) with non transgenic mice (wt) and mice with a normal number (20) of CTG
repeat (DM20-954), to confirm that the observed abnormalities were not due tooverexpression of the human transgene. Mice were analyzed at the ages of
3.5 months, 5 to 6 months and 10 months. They were housed and handled
according to French governmental ethics guidelines. Transgenic mice were
obtained from B6/D2 F1 injected eggs. They were backcrossed with C57BL/6
mice (Charles River laboratories) to ensure that the C57BL/6 background
accounted for more than 98% of the genome in both transgenic and non-
transgenic control mice (over 6 backcrosses).
2.2. Glucose tolerance tests
Glucose (1 mg/g) was injected intraperitoneally, under anesthesia (pento-
barbital), into mice aged 3.5, 5 to 6 or 10 months, after a 16-h fast. Blood
samples were taken from the tail vein after 0, 10, 20, 30 and 60 min. Glucose
levels were measured with a glucometer (Onetouch II; Lifescan). Plasma was
recovered from each blood sample, and insulin concentration was quantified by
ELISA (rat ultra-sensitive insulin ELISA kit; Christal Chem. Inc).
2.3. Insulin tolerance tests
Mice were subjected to an insulin tolerance test at the same ages. The mice
were fasted for 16 h. A basal blood sample was then taken from the tail vein and
the mice received an intraperitoneal injection of insulin (0.75 U/kg of Novolin
R, Novo Nordisk Pharmaceutical Industries). Blood samples were taken 15, 30
and 60 min after injection and glucose levels were determined as described
above. Results are expressed as percentages of initial blood glucose
concentration.
2.4. RNA isolation
Mice were sacrificed by cervical dislocation, according to ethical guidelines.
Skeletal muscle (soleus), liver, pancreas, hypothalamus/thalamus and perigo-
nadal white adipose tissue were frozen in liquid nitrogen and stored at −80 °C.
Total RNA was extracted from frozen tissues, using RNeasy mini kits from
Qiagen (Ref 74104), used according to the manufacturer’s protocol. RNA was
quantified by spectrophotometry and its quality was checked by electrophoresis
in a 1% (w/v) agarose gel.
2.5. RT-PCR
Reverse transcription was performed with 500 ng of total RNA and
SuperScript™ II Reverse Transcriptase (Ref 18064-022, Invitrogen), using
hexamer primers, with control of the reaction based on PCR with
oligonucleotide primers 5′-GGTGTGCACAGGAGCCAAGAGTG-3′ and 5′-
AGCTACTGAGCTGCTGGTGGGTC-3′, which amplify the TBP cDNA. All
amplifications were carried out in duplicate, using independent samples. We
used classical RT-PCR, with oligonucleotide primers 5′-GAGGATTACCTG-
CACAACG-3′ and 5′-CACAATGGTAGAGGAGACG-3′ (Sigma), binding on
either side of exon 11, for analysis of alternative splicing of the insulin receptor.
2.6. Quantitative RT-PCR
The independent duplicate RTsamples were pooled and 2 μl of a 1:10 dilution
was used for real-time quantitative PCR. Samples were amplified (40 standard
cycles) on an ABI 7700 cycler (Applied Biosystems) in triplicate or duplicate, in
two independent 25 μl reactions. The expression of the human DMPK transgene
and murine Dmpk gene was quantified with a common labeled FAM-TAMRA
probe (Eurogentech) 5′-AGGATGAGAACTACCTGTACCTGGTCATGGA-3′
spanning the end of exon 4 and the beginning of exon 5. The human and murine
gene were specifically amplified with two different pairs of oligonucleotides
(Eurogentech) located in a non homologous region of the human and murine
exons 4 and 5. Oligonucleotides for the human gene were 5′-GGAGAGG-
GACGTGTTG-3′/5′-CTTGCTCAGCAGTGTCA-3′ and those specific of the
murine gene were 5′-GGAAGAAAGGGATGTATTA-3′/ 5′-CTCAGCAGCGT-
TAGCA-3′. For quantification of the IR isoforms (+/−exon 11), real-time
quantitative PCR was carried out with the same Absolute qPCR ROXMIX, with
specific labeled FAM-TAMRA probes (Eurogentech) and oligonucleotides
Fig. 1. Age-dependent expression of the human DMPK transgene and the
endogenous Dmpk gene in transgenic mice. DMPK transgene (A) and Dmpk
endogenous (B) transcription levels were determined by real-time quantitative
PCR, with normalization according to 18S expression, in various insulin-
responsive tissues and in pancreas from 6- and 10-month-old DM300-328 male
mice (pool n=4–6). Expression levels are expressed in arbitrary units. ⁎pb0.05;
⁎⁎pb0.01.
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(+exon11). Oligonucleotides 5′-TTCGAGGATTACCTGCACAA-3′ and 5′-
ACATTCCCCACCTCTTCAAG-3′ were used for IRA and oligonucleotides 5′-
GGAAATCTGGAAGTGTGAGTGT-3′ and 5′-TCGAGGATTACCTGCA-
CAAC-3′ for IRB. Both pairs of primers were located in exons 10 and 12. The
corresponding probes were 5′-TTTTTGTTCCCAGGCCATCCCGAAAGC-
GAA-3′ spanning the end of exon 10 and the beginning of exon 12 for the
amplification of IRA and 5′-TCCCCAGGAAAAACCTCTTCAGGCAATGGT-
3′ spanning the end of exon 11 and the beginning of exon 12 for the amplification
of IRB. The results obtained for DMPK or IR isoform quantification were
normalized with a FAM-TAMRA 18S genomic control kit (RT-CKFT-18S;
Eurogentech).
2.7. Immunohistochemistry
Dissected mouse pancreata were rapidly frozen in liquid nitrogen and stored
at −80 °C. Cryosections (10 μm) were prepared with a Leica cryostat set at
−20 °C. Sections were fixed by incubation for 15 min at room temperature with
4% (w/v) paraformaldehyde, and washed three times in 1× PBS for 2 min each.
Sections were then permeabilized by incubation in a solution containing
0.05% (v/v) Triton X-100 and 10% (v/v) normal horse serum in 1× PBS for
30 min at room temperature and washed in 1× PBS. Double immunostaining
was performed by simultaneous incubation with guinea pig anti-insulin and
rabbit anti-glucagon antibodies (Dakocytomation) at 4 °C overnight. Sections
were washed and incubated for 1 h at room temperature with an Alexa anti-
guinea pig IgG and a fluorescein-conjugated anti-rabbit IgG (Jackson
Immunoresearch Laboratories Inc.). Sections were washed three times with
1× PBS, for 5 min each, and were then sealed with Vectashield containing DAPI
(Vector Laboratories). Immunohistochemical signals were acquired with a
Leica fluorescence microscope. Independent sections were also stained with
hematoxylin–eosin.
2.8. Fluorescent in situ hybridization
Frozen sections (6 μm) of the various insulin-sensitive tissues were dried for
30 min, fixed by incubation in 4% (w/v) paraformaldehyde for 15 min at room
temperature, and washed five times in 1× PBS, for 2 min each. Sections were
permeabilized by incubation in 2% (v/v) acetone PBS (pre-chilled at −20 °C) for
5 min. They were then incubated in 30% (v/v) formamide and 2× SSC for
10 min, hybridized with probe (1 ng/μl) for 2 h at 37 °C in buffer (30% (v/v)
formamide, 2× SSC, 0.02% (w/v) BSA, 66 μg/ml yeast tRNA, 2 mM vanadyl
complex), and washed for 30 min in 30% (v/v) formamide/2× SSC at 50 °C and
then for 30 min in 1× SSC at 20 °C. Sections were then mounted in Vectashield
with DAPI (Vector Laboratories). We used HPLC-purified 2-O-methyl RNA 20-
mers (Proligo) with CAG-repeats and 5′ end-labeled with fluorescein as probes.
2.9. Combined FISH/immunofluorescence
Frozen sections (6 μm) of adipose tissue and pancreas were treated following
the same FISH procedure as described before, with the exception of the
permeabilization step during which we used a permeabilizing/blocking reagent
(0,1% Triton X-100, 1% BSA and 3,75% goat serum in 1× PBS). After the last
wash in 1× SSC, slides were incubated overnight at 4 °C with 1:300 rabbit anti-
HSL primary antibody (anti Hormone Sensitive Lipase, Santa Cruz) or 1:50 rat
anti-insulin (R&D Systems) to label adipocytes and β cells, respectively. After
three washes in 1× PBS, sections were blocked in 1% BSA and 3,75% goat
serum in 1× PBS for 30 min at room temperature. They were then incubated with
the Texas Red-conjugated secondary antibodies (Vector laboratories) for 30 min
at room temperature. Following incubation, slides were washed three times with
1× PBS and nuclei were stained with DAPI using VECTASHIELD (Vector
laboratories).
2.10. Calculations and statistical analyses
Statistical analyses were carried out with the StatView program 5.0 (SAS
Institute Inc.), using unpaired Student’s t tests. For all analyses, p valuesb0.05
were considered significant. Results are expressed as means±SEM.3. Results
3.1. The human DMPK transgene is expressed in various tissues
in mice
In order to determine if the CTG repeat expansion could
affect IR splicing in different tissues, we first investigated
expression of the human DMPK transgene in several tissues
from mice carrying DM1 expansions. This analysis was per-
formed in 6- and 10-month-old mice, to follow possible age-
dependent changes in the level ofDMPK expression. We carried
out real-time quantitative RT-PCR with specific probes and
primers for human DMPK transcripts. We analyzed the quad-
riceps, soleus, liver, adipose tissue, pancreas and the hypothal-
amus/thalamus area.
We detected DMPK transgene expression in the various
tissues with a pattern of expression very similar to the Dmpk
endogenous gene. Interestingly, we observed that DMPK trans-
gene expression (as well as endogenous Dmpk expression)
varied with age, in a tissue-specific manner (Fig. 1). In quad-
riceps, soleus, liver and adipose tissue, DMPK transcript levels
increased between 6 and 10 months, whereas they decreased
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thalamus area. Expression was strongest in the soleus at
6 months of age and at 10 months of age and was the lowest
in pancreas. In addition, expression of the DMPK transgene and
endogenous Dmpk gene varied between muscles types (soleus
versus quadriceps in this study and unpublished data). Fluo-
rescent in situ hybridization experiments showed that expanded
DMPK transgene RNA accumulated as foci in nuclei of soleus
and hypothalamus in DM300-328 mice (Fig. 2). Rare foci were
also observed in adipose tissue and pancreas. NoRNA foci could
be found in the liver of these mice.
3.2. DM300-328 mice present a muscle- and age-specific change
in the splicing of insulin receptor RNA
Transcription of the IR gene results in the production of two
alternatively spliced isoforms: IRA (−exon11) and IRB
(+exon11). These two isoforms differ in function and are
expressed in a tissue-specific manner [26]. IRA has a higher
affinity for insulin and a higher rate of internalization than IRB
[27,28], whereas IRB has a higher level of kinase activity and is
considered to transmit the insulin signal more efficiently than
IRA [29]. The presence or absence of exon 11 promotes differ-Fig. 2. MutantDMPK transcripts formed nuclear RNA foci in several insulin-respons
a (CAG)20 fluorescent probe in adipose tissue, soleus and pancreas from DM300-328
in the cell nuclei that are stained with DAPI. FISH experiments were combined with
pancreas and hormone-sensitive lipase rich adipocytes in perigonadal White Adiposent localization of the two receptor types, which is coupled with
different function [30].
Real-time quantitative RT-PCR with probes specific for the
two insulin receptor isoforms, IRA and IRB, showed that the
two isoforms were distributed abnormally in the soleus of 10-
month-old DM300-328 mice, in which IRB (+exon 11)
predominated. We observed a ∼50% increase in IRB RNA
levels and a ∼40% decrease in the level of IRA RNA (Fig. 3A).
No abnormality in receptor isoform expression was observed in
6-month-old mice. No isoform switch was observed in the
quadriceps, suggesting that the splicing defect in the DM300-
328 mice was muscle-specific (data not shown). This analysis
also revealed that the levels of IR isoforms decreased with age
in the soleus, both in DM300-328 and in controls.
3.3. Molecular abnormalities are also present in other
insulin-responsive tissues and in the pancreas
Based on published results and the known importance of
insulin in metabolic homeostasis, we extended our molecular
analyses to other insulin-responsive tissues and in pancreas. In
liver, at 6 months of age, DM300-328 mice had lower total IR
mRNA levels than controls, with about 80% less of each isoformive tissues and in pancreas from transgenic mice. Nuclear foci were detected with
mice only. Foci were not detected in liver. White arrows indicate green RNA foci
immunofluorescence staining for the identification of insulin-secreting cells in
e Tissue (WAT).
Fig. 3. Abnormal expression of IRA and IRB in mice expressing mutant DMPK transcripts. The levels of expression of the two IR isoforms were determined by RT-
PCR (left) or real-time PCR (right), with normalization according to 18S levels in wild-type mice (wt), in control DM20-954 mice with 20 CTG repeats (DM20) and in
DM300-328 mice carrying N350 CTG expansions (DM300). Isoform levels were determined in the soleus (A), liver (B), adipose tissue (C), pancreas (D) and
hypothalamus/thalamus (E) of 6- and 10-month-old males (n=4–6/group). Tbp was used as an internal control in RT-PCR experiments. ⁎pb0.05; ⁎⁎pb0.01;
⁎⁎⁎pb0.001.
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10 months of age. RT-PCR and real-time quantitative RT-PCR
results at 10 months revealed an ∼20% increase in IRB RNA
levels, together with an ∼20% decrease in the already low level
of IRA RNA in DM300-328 mice (pb0.05 DM300-328 com-
pared to wt and DM20 controls). Molecular studies on adipose
tissue also showed changes in the distribution of the insulin
receptor mRNA isoforms, but only in 10-month-old DM300-
328 mice (Fig. 3C). IRBmRNA levels in DM300-328 mice were
about 40% higher than those in control mice, while IRA levels
were about 50% lower (pb0.001). We next investigated the
distribution of IR mRNA isoforms in the pancreas of DM300-
328 and control wt mice. RT-PCR and real-time quantitative RT-
PCR showed that the levels of both IRA and IRB isoforms were
about 20% lower in 6-month-old DM300-328 mice than in wtFig. 4. Glucose tolerance test, secretion and insulin sensitivity in transgenic mice and
at the indicated time points before and after intraperitoneal injection of glucose (1 mg/
and in 16 h fasted control wild-type and DM20-954 males (wt and DM 20), n=6/grou
intraperitoneal injection of insulin (0.75 IU/kg), in the same 16 h fasted mice (n=6/
10-month-old males. Results are expressed as means±SEM. (D) Mean weight of wt, D
transgenic versus both control groups by unpaired, two-tailed Student's t test.mice (pb0.01) (Fig. 3D). At 10 months, DM300-328 mice had
higher IRA and lower IRB levels than wt mice (Fig. 3D). This led
to a switch in the relative distributions of the two isoforms, with
IRA becoming more abundant than IRB.
3.4. Higher levels of insulin receptor expression are observed
in the hypothalamus/thalamus area of DM300-328 mice
Low levels of cerebral glucose utilization have been reported
in DM1 patients [31,32], suggesting that these patients have
impaired cerebral glucose metabolism. Neuronal IRs are known
to have an impact on peripheral glucose metabolism [33]. We
then investigated the expression of insulin receptor isoforms in
the brains of DM300-328 mice. We focused on the hypothal-
amus/thalamus area, in which the insulin receptor is mostcontrols. Blood glucose (A) and serum insulin (B) concentrations were measured
g body weight) in 16 h fasted DM300-328males with CTG expansions (DM 300)
p. Blood glucose (C) was determined at the indicated time points before and after
group). (3.5 m) 3.5-month-old males. (5–6 m) 5- to 6-month-old males. (10 m)
M20 and DM300 males at 3.5, 5–6 and 10 months of age. ⁎pb0.05; ⁎⁎pb0.01:
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intake, body weight, energy disposal, fuel metabolism and
reproduction) [34]. RT-PCR and real-time quantitative RT-PCR
analyses showed no difference in the levels of expression of the
IRA isoform (with IRA the most strongly expressed, and IRB
barely detectable) between DM300-328 mice and controls, at
6 months. However, IRA transcript levels were higher (+40%,
pb0.001) in the hypothalamus/thalamus area of 10-month-old
DM300-328 mice than in controls (Fig. 3E). IRB transcript
levels were too low for quantification.
3.5. DM1 transgenic mice show abnormal glucose and insulin
responses
In order to investigate if the changes in IR isoforms distri-
bution and levels observed in various tissues of the in DM300-
328 mice could have some impact on glucose metabolism,
glucose tolerance tests were performed after a long 16-h fasting
period, in mice aged 3.5, 5–6 and 10 months. Similar results
were obtained in pilot experiments for males and females.
Therefore, we chose to carry on our experiments only with
males, as presented. DM300-328 males weighed 8 to 25% less
than wt and DM20 controls (Fig. 4D). Basal hyperglycemia and
glucose intolerance were detected in DM300-328 mice at 3.5
and 6months of age but not in controls (DM20-954) or wild-type
mice (pb0,05, Fig. 4A). This abnormal glucose response was
associated with a lack of glucose-stimulated insulin response
(Fig. 4B). Strikingly, no glucose intolerance was detected in the
DM300-328 mice at 10 months of age, despite the persistence of
the glucose-stimulated insulin response defect (Fig. 4 A and B).
Insulin tolerance tests in these mice showed no significant
difference, at the ages of 3.5 and 6months, between DM300-328
and control mice (Fig. 4C). However a slight insulin hyper-
sensitivity was observed in 10-month-old DM300-328 mice
(pb0.05). Histological analysis after the labeling of pancreatic
islets with hematoxylin–eosin or the detection of immunoflu-
orescent β cells revealed no differences in the number or size of
pancreatic islets or changes in the proportion of β cells (data not
show).
4. Discussion
Cell culture experiments, observations in DM1 patients and
mouse models have shown that expanded CUG containing
mRNA are toxic and alter splicing regulation of various
transcripts. In this study, we investigated the splicing regulation
of IR, known to be affected in DM1 patients muscles and in
cellular models [25,35–39]. In our mice model, the human
DMPK gene is controlled by its own promoter and is embedded
in large human genomic sequences over 45 kb, probably con-
taining most of the transcriptional regulatory sequences. Using
quantitative RT-PCR, we observed that expression patterns of
the DMPK transgene and the Dmpk endogenous gene were very
similar in skeletal muscles, adipose tissue, liver and pancreas,
although lower for the DMPK transgene (e.g. the level of
expression of the endogenous Dmpk gene in the gastrocnemius
of 3-month-old mice is ∼5 times higher than that of the DMPKtransgene [20]). We also observed that the levels of expression
of both genes are tissue-specific and varied between 6 and
10 months. These data prompted us to investigate the possible
splicing defects these tissues, at different ages, and the con-
sequences that these defects could have on glucose metabolism.
At the age of 6 months, expression levels of both IR isoforms,
IRA and IRB, were similar between DM300-328 in soleus,
adiposes tissues and hypothalamus. However, molecular
analyses clearly showed that DM300-328 mice had much
lower (80% lower) levels of insulin receptor mRNA (IRA+IRB)
in the liver than the controls. The same mice also had lower
levels of IRmRNA in the pancreas (20% lower). At this stage, it
is difficult to explainwhy at 6months of age, mice expressing the
mutant DMPK gene showed a decrease in the levels of IR
mRNA. Liver and pancreas are not the tissues with the highest
expression of DMPK. DMPK showed a much lower expression
in liver and pancreas than in muscles in which IR expression is
not affected at 6 months. However, we cannot exclude a high
level of transgene expression in specific cell types in these two
tissues that would affect IR expression in particular cells. Thus,
factors involved in IR gene regulation at transcriptional or
posttranscriptional levels (such as RNAmaturation and stability)
could be affected by the expanded transgene. These factors may
be tissue-specific and/or could be more affected by the CTG
repeat in the liver and pancreas of the DM300-328 mice. It has
been reported that IR expression at the RNA and protein levels is
decreased in DM1 patients muscle [35] but there is no data on IR
expression in the pancreas and liver of DM1 patients. Further-
more, expanded CUG-containing transcripts have been reported
to sequester transcription factors such as Sp1 [18], and may have
a deleterious impact on IR transcription. Even more surprising
was the fact that the decrease of 80% in liver and of 20% in
pancreas were no longer observed at 10 months of age. Instead,
DM300-328 showed a shift in the IRA and IRB isoforms
distribution in liver and pancreas, compared to wt and DM20
control mice of the same age. Abnormal IRA and IRB isoforms
distribution was also observed in soleus, and adipose tissue.
These data suggest that the expression of RNA carrying CUG
expansion in transgenic mice disturbed the regulation of the IR
gene splicing as shown in cell culture and in DM1 muscles.
Furthermore, it shows that the isoforms distribution of IRA and
IRB is affected in all the insulin-responsive tissues expressing
the mutant DMPK RNA and in an age-dependent manner. It is
interesting to mention here that we observed in most DM300-
328 mice tissues (except pancreas and hypothalamus), a
significant increase of mutant DMPK transcripts in the older
mice. Aswe already know that the level of expanded CUG repeat
transcripts is critical to induce phenotype and splicing
abnormalities in our mice [20], it is tempting to speculate that
the IR splicing defects observed at 10 months could be linked to
the increased of DMPK transgene expression at that age. On the
other hand, this study showed that IR expression decreases with
age in most control tissues. It is therefore possible that IR
splicing regulation varied with age and that the mechanisms
involved in agedmice aremore “sensitive” to CUG toxic repeats.
Our physiological investigations in DM300-328 mice
suggest that the trans-effect of expanded DMPK RNA and the
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abnormalities observed in these mice. However, the distur-
bances observed in DM300-328 mice and DM1 patients are
different. We observed no hyperinsulinemia associated with
glucose intolerance and insulin resistance similar to that
described in DM1 patients. Instead, DM300-328 mice showed
glucose intolerance, which disappeared with age, and a defect in
glucose-stimulated insulin response. Quantitative RT-PCR
analyses in the insulin-responsive tissues suggested that these
differences in metabolic status between the two species might
arise, among other possibilities, from differences in the tissue-
specific distribution of IR mRNA isoforms between C57BL/6
mice and humans. For example, IRB is the predominant isoform
in human skeletal muscle, whereas IRA predominated in the
skeletal muscles of wild-type C57BL/6 mice [26]. The different
regulation of the IR splicing between C57BL/6 mice and human
underlines that the regulation of the insulin pathways may vary
between the two species. Mice on a C57BL/6 background may
not fully recreate the DM1 insulin resistance features. However
they remain a very useful tool to study the molecular effect of
CUG repeat containing RNA on RNA splicing in vivo.
The mechanisms by which CUG repeats-containing RNA
exert a trans-effect on splicing regulation remain unclear, but
many studies recently carried out, have provided a large body of
information (for review see [17]). There is growing evidence to
suggest that the retention of DMPK mRNA with CUG expan-
sions alters RNA metabolism by titration and/or by changes in
the function of CUG binding proteins such as MBNL1 and
CUG-BP1 respectively members of the muscleblind-like family
and the CELF family . Recent data suggest that CUG-BP1 and
HnRNP H may regulate the equilibrium of splice site selection
by antagonizing MBNL1 facilitation of insulin receptor exon 11
splicing in a dose-dependent manner [25,36,38,40]. The pre-
dominant isoform of the insulin receptor may therefore depend
on the tissue-specific or age-dependent expression profiles of
these two antagonist proteins (or other members of the
corresponding protein families). Thus, further molecular
analyses of the expression of proteins from the CELF and
muscleblind-like families in various tissues in adult transgenic
mice may improve our understanding of tissue-specific and age-
dependent insulin receptor mRNA processing defects. The
splicing abnormalities that we observed in DM300-328 mice at
10 months of age showed a shift towards the overrepresentation
of isoform B with inclusion of exon 11 in the soleus muscle. In
DM1 patients, CTG expansions lead to the increase of isoformA
and the exclusion of exon 11 [25]. Taken together with the
observation that the repartition of isoforms A and B is also
inverted in control human and mouse skeletal muscles, these
results suggest that the regulation of exon 11 splicing might be
different between the two species. It has been clearly
demonstrated that CUG-BP1, hnRNP H and MBNL1 are able
to bind the human IR intron 10 sequences allowing the
regulation of exon 11 splicing. CUG-BP1 and hnRNP H form
a suppressor required for the repression of exon 11 inclusion and
MBNL1 induces exon 11 inclusion [25,36,38,40]. However,
these proteins can also promote an opposite splicing pattern for
cardiac troponin T (cTNT): MBNLl has been shown to favorcTNT exon 5 skipping while CUB-BP1 is involved in its
inclusion [40]. Therefore, these proteins can have different roles
in exon splicing, probably depending on the context and/or the
number of binding sites in the splicing regulatory sequences.
Analyses of the mouse Cug-bp1, Mbnl1 and hnRnp H proteins
binding to the mouse intron 10 and functional experiments using
mouse Insulin receptor minigenes are required to determine if
and how the regulation of the mouse exon 11 differs from the
human Insulin Receptor exon 11 splicing regulation.
5. Conclusion
In conclusion, we showed for the first time that DMPK tran-
scripts carrying CUG expansion affect IR splicing in transgenic
mice. Furthermore, these mice provided evidence that IRA and
IRB isoforms distribution can be affected not only in muscles
but also in other insulin-responsive tissues and in pancreas. At
this stage, it is difficult to relate the molecular abnormalities and
the physiological abnormalities observed in the DM300-328
mice. Complex interactions can occur between and among
insulin-responsive tissues and in pancreas, mediated by factors
that promote cross-talk in insulin-driven responses. Furthermore,
we observed complex age-dependent changes of the IR A and B
isoforms expression in all these tissues. At 6 months of age, the
lack of glucose-stimulated insulin response and glucose
intolerance could be explained by the decrease of IRA and IRB
expression in pancreas and liver and/or by others factors (such as
defects of transcription factors involved in the regulation of the
Insulin gene expression). At 10 months of age, despite the
persistence of a glucose-stimulated insulin-response defect, the
glucose tolerance appeared normal. However, multiple splicing
defects were observed in all the tissues that were investigated.
One possible explanation is that combined variations of IRA and
IRB expression in the different tissues could induce a higher
insulin sensitivity of the tissues involved in the uptake and/or
storage of glucose resulting in a normal glucose tolerance.
Finally, the different regulation of IR exon 11 splicing between
mice and human and the different physiological manifestations
observed in transgenic mice compared to DM1 patients indicate
that mouse is not a good model for the study of DM1 features that
involve insulin regulation. However, it remains possible that, as
observed in mice, IR splicing regulation could be affected not
only in muscles but also in other tissues in DM1 patients. The
resulting IR splicing defects in different tissues might then
participate to the metabolic syndrome observed in DM1 patients.
It is also interesting to keep in mind that the splicing molecular
defects could be tissue-specific and age-dependent.
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